As America’s newest prescription painkiller Zohydro prepares to hit the markets in March, critics have embarked in one final effort to halt its release. Just earlier this week, more than 40 prominent health care, consumer and addiction treatment groups—including CASAColumbia, Blue Cross Blue Shield, and Hazelden—signed a letter to the FDA to repeal Zohydro. “In Read more…